Mitochondrial oxidative phosphorylation disorder due to mitochondrial DNA anomalies

Mitochondrial oxidative phosphorylation (OXPHOS) disorders due to mitochondrial DNA (mtDNA) anomalies are a clinically heterogeneous group of rare genetic conditions caused by mutations, deletions, or rearrangements in the mitochondrial genome. Since mitochondria are responsible for generating the majority of cellular energy through the oxidative phosphorylation system, defects in mtDNA impair energy production and predominantly affect tissues with high energy demands, including the brain, skeletal muscle, heart, liver, kidneys, and sensory organs (eyes and ears). These disorders encompass a wide spectrum of well-recognized clinical syndromes such as MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes), MERRF (myoclonic epilepsy with ragged red fibers), Kearns-Sayre syndrome, Leber hereditary optic neuropathy (LHON), and chronic progressive external ophthalmoplegia (CPEO), among others. Key symptoms vary depending on the specific mtDNA anomaly and the degree of heteroplasmy (the proportion of mutant versus normal mtDNA within cells), but commonly include exercise intolerance, muscle weakness (myopathy), seizures, stroke-like episodes, progressive external ophthalmoplegia, ptosis, sensorineural hearing loss, cardiac conduction defects or cardiomyopathy, diabetes mellitus, lactic acidosis, and developmental regression. Neurological involvement is frequent and can manifest as encephalopathy, ataxia, cognitive decline, or peripheral neuropathy. Multisystem involvement is the hallmark of these conditions, and clinical severity ranges from mild, late-onset symptoms to severe neonatal or infantile presentations with rapid deterioration. Currently, there is no curative treatment for mitochondrial OXPHOS disorders due to mtDNA anomalies. Management is primarily supportive and symptomatic, including nutritional supplementation with coenzyme Q10, L-carnitine, B vitamins, and other cofactors, although evidence for their efficacy remains limited. Seizure management, cardiac monitoring, endocrine management (e.g., for diabetes), physical therapy, and avoidance of mitochondrial toxins (such as certain medications like valproic acid and aminoglycosides) are important components of care. Genetic counseling is essential given the maternal inheritance pattern and variable expressivity. Research into gene therapy and novel pharmacological approaches is ongoing.

Common questions about Mitochondrial oxidative phosphorylation disorder due to mitochondrial DNA anomalies